Table II.
Anti VEGF agents beyond progression and second line after previous exposure to anti VEGF agents.
| Study (year) | Treatment | Patients | End points (months) | HR (95% CI) | p value |
|---|---|---|---|---|---|
| Bennouna et al. ML18147 (2013) | FOLFOX or FOLFIRI +/− Bevacizumab beyond progression | 820 | OS (9.8 vs. 11.2) | 0.83 (0.71-0.97) | 0.0211 |
| 409 vs. 411 | PFS (4.1 vs. 5.7) | 0.67 (0.58-0.78) | <0.001 | ||
| van Cutsem et al. VELOUR (2012) | placebo + FOLFIRI vs. FOLFIRI + Aflibercept | 1401 (1226) | OS (1206 vs. 13.5) | 0.81 (0.71–0.93) | 0.0032 |
| 614 vs. 612 | PFS (4.67 vs. 6.90) | 0.75 (0.66-0.86) | <0.0001 | ||
| Tabernero et al RAISE (2015) | placebo + FOLFIRI vs. FOLFIRI + Ramucirumab | 1072 | OS (11.7 vs. 13.3) | 0.84 (0.73-0.97) | 0.0219 |
| 536 vs. 536 | PFS (4.5 vs. 5.7) | 0.79 (0.69-0.90) | <0.0005 |